RECRUITING Not applicable ClinicalTrials.gov

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

Sponsor: Case Western Reserve University • ClinicalTrials.gov ID: NCT07852273

Registry updated: 2026-10-01

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with Inflammatory Bowel Disease (IBD), compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with Crohn's Disease (CD) as a proof of principle that could be tested later in other IBD subtypes (ulcerative colitis or others specific surgical conditions).

Interventions

Sucralose (non-nutritive sweetener) (Other)
Participants will consume 2 sachets/day during the exposure period resulting in the following daily dose: sucralose 2.5mg/kg. This dose is below the acceptable daily intakes (ADI) of 5mg/kg.

Eligibility criteria

Inclusion Criteria: * Age range from 18 to 75 years * Male or female * Documented diagnosis of Crohns disease. CD outpatients in remission; Harvey Bradshaw- index in remission (\<6 score) * Capable of providing consent to participate. * Able to complete daily surveys and take oral nutrition * Able to record meal intake * Healthy controls with no diagnosis of Irritable Bowel Disease IBD or Irritable Bowel Syndrome (IBS) Exclusion Criteria: * Short bowel syndrome * Hospitalized patients * Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients * Known drug abuse * Known parasitic disease of the digestive system * Symptomatic intestinal stricture/narrowing * Presence of an ostomy * Known active malignancy * Antibiotic use within last 14 days * Well-founded doubt about the patient's cooperation. * Existing pregnancy or lactation * History of \<1 natural bowel movements per 3 consecutive days * Unable to access technology that permits the daily completion of study related activities * Change in IBD medication within past 4 weeks * Body mass Index \<16 kg/m or ≥40 kg/m * Documented C.difficile colitis within four weeks of screening * Bariatric surgery * Phenylketonuria

Conditions

Inflamatory Bowel Disease Crohn Disease (CD)

Locations

UH Minoff Health Center — Chagrin Falls, Ohio, United States
University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
UH Westlake Health Center — Westlake, Ohio, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment